BioCardia (BCDA) has provided an update.
CellProthera and BioCardia, Inc. have announced the successful completion of a Phase II trial for ProtheraCytes, a cutting-edge cell therapy for treating acute myocardial infarction. Riding on this success, the companies are gearing up to advance their collaboration into Phase III, demonstrating promise in the field of regenerative medicine and potentially sparking investor interest in the burgeoning area of cell-based therapies.
For an in-depth examination of BCDA stock, go to TipRanks’ Stock Analysis page.
